Heterogeneous Proliferative Potential of Occult Metastatic Cells in Bone Marrow of Patients with Solid Epithelial Tumors

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2002 Feb 21

PMID 11854519

Citations 35

Authors

Oender Solakoglu

Christine Maierhofer

Georgia Lahr

Elisabeth Breit

Peter Scheunemann

Isabella Heumos

Uwe Pichlmeier

Gunter Schlimok

Ralph Oberneder

Manfred W Kollermann

Jens Kollermann

Michael R Speicher

Klaus Pantel

Affiliations

Soon will be listed here.

Abstract

Bone marrow is a major homing site for circulating epithelial tumor cells. The present study was aimed to assess the proliferative capacity of occult metastatic cells in bone marrow of patients with operable solid tumors especially with regard to their clinical outcome. We obtained bone marrow aspirates from 153 patients with carcinomas of the prostate (n = 46), breast (n = 45), colon (n = 33), and kidney (n = 29). Most of the patients (87%) had primary disease with no clinical signs of overt metastases [tumor-node-metastasis (TNM)-stage UICC (Union Internationale Contre le Cancer) I-III]. After bone marrow was cultured for 21-102 days under special cell culture conditions, viable epithelial cells were detected by cytokeratin staining in 124 patients (81%). The cultured epithelial cells harbored Ki-ras2 mutations and numerical chromosomal aberrations. The highest median number of expanded tumor cells was observed in prostate cancer (2,619 per flask). There was a significant positive correlation between the number of expanded tumor cells and the UICC-stage of the patients (P = 0.03) or the presence of overt metastases (P = 0.04). Moreover, a strong expansion of tumor cells was correlated to an increased rate of cancer-related deaths (P = 0.007) and a reduced survival of the patients (P = 0.006). In conclusion, the majority of cancer patients have viable tumor cells in their bone marrow at primary tumor diagnosis, and the proliferative potential of these cells determines the clinical outcome.

Citing Articles

Autophagy is required for mammary tumor recurrence by promoting dormant tumor cell survival following therapy.

Dwyer S, Ruth J, Seidel H, Raz A, Chodosh L Breast Cancer Res. 2024; 26(1):143.

PMID: 39425240 PMC: 11488247. DOI: 10.1186/s13058-024-01878-7.

The lactate sensor GPR81 regulates glycolysis and tumor growth of breast cancer.

Ishihara S, Hata K, Hirose K, Okui T, Toyosawa S, Uzawa N Sci Rep. 2022; 12(1):6261.

PMID: 35428832 PMC: 9012857. DOI: 10.1038/s41598-022-10143-w.

STAT3 Signaling in Breast Cancer: Multicellular Actions and Therapeutic Potential.

To S, Dmello R, Richards A, Ernst M, Chand A Cancers (Basel). 2022; 14(2).

PMID: 35053592 PMC: 8773745. DOI: 10.3390/cancers14020429.

Interleukin 11 (IL-11): Role(s) in Breast Cancer Bone Metastases.

Maroni P, Bendinelli P, Ferraretto A, Lombardi G Biomedicines. 2021; 9(6).

PMID: 34201209 PMC: 8228851. DOI: 10.3390/biomedicines9060659.

Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone.

Owen K, Gearing L, Zanker D, Brockwell N, Khoo W, Roden D EMBO Rep. 2020; 21(6):e50162.

PMID: 32314873 PMC: 7271653. DOI: 10.15252/embr.202050162.

References

Harbeck N, Untch M, Pache L, Eiermann W . Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer. 1994; 69(3):566-71. PMC: 1968873. DOI: 10.1038/bjc.1994.103. View

Pantel K, Cote R, Fodstad O . Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999; 91(13):1113-24. DOI: 10.1093/jnci/91.13.1113. View

Pantel K, Dickmanns A, Zippelius A, Klein C, Shi J, Schlimok G . Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst. 1995; 87(15):1162-8. DOI: 10.1093/jnci/87.15.1162. View

Heiss M, Allgayer H, Gruetzner K, Funke I, Babic R, Jauch K . Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med. 1995; 1(10):1035-9. DOI: 10.1038/nm1095-1035. View

Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O . Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996; 347(9002):649-53. DOI: 10.1016/s0140-6736(96)91203-9. View

Allgayer H, Heiss M, Riesenberg R, Grutzner K, Tarabichi A, Babic R . Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res. 1997; 57(7):1394-9. View

Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich C . Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000; 342(8):525-33. DOI: 10.1056/NEJM200002243420801. View

Ellis C, Clark G . The importance of being K-Ras. Cell Signal. 2000; 12(7):425-34. DOI: 10.1016/s0898-6568(00)00084-x. View

Lahr G . RT-PCR from archival single cells is a suitable method to analyze specific gene expression. Lab Invest. 2000; 80(9):1477-9. DOI: 10.1038/labinvest.3780155. View

10.

Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J . Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol. 2001; 19(4):960-71. DOI: 10.1200/JCO.2001.19.4.960. View

11.

Leinung S, Wurl P, Schonfelder A, Weiss C, Roder I, Schonfelder M . Detection of cytokeratin-positive cells in bone marrow in breast cancer and colorectal carcinoma in comparison with other factors of prognosis. J Hematother Stem Cell Res. 2001; 9(6):905-11. DOI: 10.1089/152581600750062354. View

12.

Braun S, Schindlbeck C, Hepp F, Janni W, Kentenich C, Riethmuller G . Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol. 2001; 19(2):368-75. DOI: 10.1200/JCO.2001.19.2.368. View

13.

Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G . ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res. 2001; 61(5):1890-5. View

14.

Lahr G, Stich M, Schutze K, BLUMEL P, Posl H, Nathrath W . Diagnosis of papillary thyroid carcinoma is facilitated by using an RT-PCR approach on laser-microdissected archival material to detect RET oncogene activation. Pathobiology. 2001; 68(4-5):218-26. DOI: 10.1159/000055927. View

15.

Carney D, Gazdar A, Bepler G, Guccion J, Marangos P, Moody T . Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 1985; 45(6):2913-23. View

16.

Haliassos A, Chomel J, Grandjouan S, KRUH J, Kaplan J, Kitzis A . Detection of minority point mutations by modified PCR technique: a new approach for a sensitive diagnosis of tumor-progression markers. Nucleic Acids Res. 1989; 17(20):8093-9. PMC: 334949. DOI: 10.1093/nar/17.20.8093. View

17.

Cote R, Rosen P, Lesser M, Old L, Osborne M . Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol. 1991; 9(10):1749-56. DOI: 10.1200/JCO.1991.9.10.1749. View

18.

Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J . Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer. 1991; 27(11):1461-5. DOI: 10.1016/0277-5379(91)90032-9. View

19.

Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G . Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet. 1992; 340(8821):685-9. DOI: 10.1016/0140-6736(92)92230-d. View

20.

Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G . Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 1993; 85(17):1419-24. DOI: 10.1093/jnci/85.17.1419. View